Malaria vaccines: results of human trials and directions of current research.
Recent human trials of candidate vaccines against the sporozoite and asexual blood stages of the malaria parasite have produced encouraging evidence that synthetic peptides and recombinant proteins can stimulate an antibody response and provide at least limited protection from malaria infection. Current research is focused on the continued evaluation of asexual blood stage antigens and on the improvement of the immunogenicity of candidate antigens through stimulation of more effective cellular and humoral responses. Efforts are also being directed toward the development of transmission-blocking vaccines based on antigens of sexual stages of the parasite.
Cattani
J A
JA
Department of Tropical Public Health, Harvard School of Public Health, Boston, Massachusetts 02115.
D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D010963:Plasmodium falciparum / Q000276:immunology*; D014612:Vaccines / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D000913:Antibodies, Protozoan; D014612:Vaccines; D014614:Vaccines, Synthetic